Gentex Q1: core sales up 2% despite production drop; China revenue falls 29% on tariffs; guides FY rev higher

GENTEX CORP

2026-Q1 EPS reported $0.46 revenue$675,443,125

Q1 consolidated net sales $675.4M (+17% YoY); core Gentex (ex-VOXX) $586.8M (+2% vs -3% global production).
GAAP EPS $0.46 (vs $0.42), adjusted EPS $0.48 (vs $0.43); net income $98.5M up from $94.9M.
FY2026 revenue guidance raised to $2.65-2.75B (from $2.60-2.70B); gross margin unchanged 34-35%.
China revenue down 29% YoY to ~$28M; cumulative IEEPA tariffs paid directly ~$42M, $15M capitalized in inventory.
Repurchased 3.3M shares for $71.6M in Q1; 32.6M shares remaining under buyback plan.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GENTEX CORP reported first quarter ended March 31, 2026 results: revenue $675.4 million, net income $98.5 million, EPS $0.46.

Period: first quarter ended March 31, 2026
Revenue: $675.4 million
Net income: $98.5 million
EPS: $0.46
Result: reported results

Exact text from the filing

medical devices, and consumer electronics, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Highlights • Net sales: Consolidated $675.4 million; core Gentex (ex‐VOXX) $586.8 million • Gross margin: Consolidated 33.8%; core Gentex (ex‐VOXX) 34.0% • Consolidated Income from operations: (GAAP) $123.7 million; core Gentex

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

GENTEX CORP filing history →

Source: SEC EDGAR

accession 0000355811-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.